[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
January 1986

Muramyl Dipeptide Enhances Survival From Experimental Peritonitis

Author Affiliations

From the Price Institute of Surgical Research (Dr Brown and Messrs Foshee and Pietsch) and the Department of Surgery (Dr Polk), University of Louisville School of Medicine.

Arch Surg. 1986;121(1):47-49. doi:10.1001/archsurg.1986.01400010053006
Abstract

• Muramyl dipeptide is a nonspecific immunostimulant derived from Freund's complete adjuvant. We determined the effect of muramyl dipeptide on two separate animal models for peritonitis. We found that administration of muramyl dipeptide to rats undergoing cecal ligation and puncture significantly reduced mortality. Similarly, mice that underwent cecal ligation alone with muramyl dipeptide administration also had a statistically significant reduction in mortality compared with untreated controls.

(Arch Surg 1986;121:47-49)

References
1.
Chedid L, Audibert F, Lefrancier P:  Modulation of the immune response by a synthetic adjuvant and analogs . Proc Natl Acad Sci USA 1976;73:2472-2475.Article
2.
Chedid L, Parant M, Parant F:  Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine) and several analogs . Immunology 1977;74:2089-2093.
3.
Polk HC Jr, Galland RB:  Enhancement of nonspecific host defense mechanisms , in Polk HC Jr (ed): Infection and the Surgical Patient . New York, Churchill Livingstone Inc, 1982, pp 101-109.
4.
Polk HC Jr, Galland RB, Ausobsky JR:  Nonspecific enhancement of resistance to bacterial infection . Ann Surg 1982;196:436-440.Article
5.
Galland RB, Heine KJ, Polk HC Jr:  Nonspecific stimulation of host defenses against bacterial challenge in immunosuppressed mice . Arch Surg 1983;118:333-337.Article
6.
Fevrier M, Birrien JL, Leclerc C:  The macrophage, target cell of the synthetic adjuvant muramyl dipeptide . Eur J Immunol 1979;8:558-562.Article
7.
Hau T, Ahrenholz D, Simmons RL:  Secondary bacterial peritonitis: The biologic basis of treatment . Curr Probl Surg 1979;16:3-65.Article
8.
Stephen M, Lowenthal J:  Continuing peritoneal lavage in high-risk peritonitis . Surgery 1979;85:603-606.
9.
Pietrich FM, Sackman W, Zak O, et al:  Synthetic muramyl dipeptide immunostimulants: Protective effects and increased efficacy of antibiotics in experimental bacterial and fungal infections in mice , in Proceedings of the 11th ICC and 19th IACC . Washington, DC, American Society of Microbiology, 1980, pp 1730-1732.
10.
Browne MK, Leslie GB:  Animal models of peritonitis . Surg Gynecol Obstet 1976;143:738-740.
11.
Hau T, Simmons RL:  Surgical pros and cons . Surg Gynecol Obstet 1977;144:755.
12.
King DW, Gurry JF, Ellis-Pegler RB, et al:  A rabbit model of perforated appendicitis with peritonitis . Br J Surg 1975;62:642-644.Article
13.
Wichterman KA, Baue AE, Chaudry IH:  Sepsis and septic shock: A review of laboratory models and a proposal . J Surg Res 1980;29:189-201.Article
14.
Baker CC, Chaudry IH, Gaines HO, et al:  Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model . Surgery 1983;94:331-335.
15.
Fraser-Smith EB, Matthews TR:  Protective effect of muramyl dipeptide and analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice . Infect Immun 1981;34:676-683.
×